image

The best stocks to buy since 1993

Our latest issue will be released in 14 days, don't miss out!

SIGN UP NOW
Updates

Creo

May 2023

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • CREO
  • Price:
  • 25p
Creo’s’ financials are of academic interest at this stage in its development. FY22 revenues were up 8% to £27.2m and composed of £0.9m from Speedboat Inject (FY21: £0.3m), a first £1.4m from Kamaptive licensing income and £24.9m consumable sales. EBITDA loss was £22m including £13.5m expensed on R&D.  Cash at the year-end was £13.1m but the company has since raised £34m before expenses. Following the re-organisation of the business in Q4 22, costs have been reduced and operational expenses in Q1 are 10% lower than the FY22 quarterly average. Meanwhile, Creo has begun to accelerate the take up of devices, with a quadrupling of trained users to 80 (91 by end March). The  range of clinical procedures being performed continues to ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

Creo (October 2023)
Creo (July 2023)
Creo Medical - Very interesting special situation (March 2023)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author

LIMITED PERIOD OFFER!

SUBSCRIBE TODAY AND SAVE £30 WITH OFFER CODE 30OFFSCSW

To access our archive of articles and to receive current issues you need to subscribe

SUBSCRIBE NOW